Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial
Breast cancer
Phase 1 Dose-Escalation Study Combines CLBR001 with ABBV-461 in Advanced Breast Cancer
Calibr, a division of Scripps Research, is evaluating an engineered autologous T cell product (CLBR001) plus an antibody-based biologic (ABBV-461) in patients with refractory, locally advanced, or metastatic breast…
NCT06878248 - Trial result
Thyroid cancer
ICAM-1 CAR-T Therapy AIC100 Yields Promising Responses in Aggressive Thyroid Cancers
In this Phase 1 dose-escalation study (NCT04420754), AIC100—a novel, ICAM-1 directed third-generation CAR T-cell therapy engineered with somatostatin receptor 2 for imaging—was evaluated in patients with…
NCT04420754 - Trial result
Colorectal cancer
EMB-01 Delivers Dual EGFR/cMET Targeting with Promising Efficacy in Heavily Pretreated mCRC
In this international phase Ib/II study, EMB-01 monotherapy at 1600 mg showed encouraging results in 48 metastatic colorectal cancer patients—particularly in left-sided, RAS/RAF wild-type mCRC—with a 24.1% partial…
- Trial result
Colorectal cancer
High miR-494 Expression Predicts Poorer Outcomes and Alters Key Gene Targets in mCRC
In the CALGB/SWOG 80405 trial, high tumor miR-494 levels were significantly associated with shorter progression‐free survival overall and in cetuximab‐treated metastatic colorectal cancer patients, while in vitro…
- Trial result
Liver and bile duct cancer
Tegavivint Targets β-Catenin in aHCC with Promising Safety and Activity
In this Phase 1/2 study, weekly intravenous tegavivint—a TBL1 inhibitor disrupting Wnt/β-catenin signaling—demonstrated manageable safety across dose levels (3–5 mg/kg) with some Grade 3 bilirubin elevations…
- Trial result
Pancreatic cancer
CM24 Combo Yields Survival Benefit in Pancreatic Cancer Patients with Specific Serum Biomarker Profiles
In this Phase 2 study, the addition of CM24 and nivolumab to chemotherapy in advanced PDAC showed modest overall improvements in survival and response rates, but subgroup analyses reveal that patients with…
- New trial
Pancreatic cancer
Phase II Study Combines NC410, FOLFIRINOX, and Immune Modulators in Metastatic PDAC
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins is investigating the safety profile and potential novel toxicities of NC410 combined with FOLFIRINOX and checkpoint inhibitors (nivolumab with or without…
NCT06941857 - New trial
Pancreatic cancer
Phase I Study Evaluates Bosentan with Gemcitabine and Nab-Paclitaxel in Unresectable Pancreatic Cancer
City of Hope Medical Center is testing the optimal dose and safety of bosentan—an endothelin receptor inhibitor—when combined with standard chemotherapy (gemcitabine and nab-paclitaxel) in patients with unresectable…
NCT04158635 - New trial
Bladder and urothelial cancer
COMPARE IT Trial Evaluates Intravesical Nadofaragene Firadenovec vs. Best Usual Care in High-Grade NMIBC
Memorial Sloan Kettering Cancer Center is conducting a comparative prospective trial to assess the effectiveness of the FDA-approved nadofaragene firadenovec gene therapy against standard intravesical regimens…
NCT06929286 - New trial
Melanoma
Cytophone Liquid Biopsy Aims for Early Detection of Metastatic Melanoma
Cytoastra’s trial in Madison is evaluating the Cytophone—a noninvasive photoacoustic flow cytometry tool that detects and counts circulating melanoma cells—to provide an early risk assessment of metastasis. This…
NCT06488365 - New trial
Melanoma
Phase 1/2 Trial of IOV-3001 Plus Lifileucel in Advanced Melanoma
Iovance Biotherapeutics in Nashville is launching an open-label study evaluating a modified interleukin-2 fusion protein (IOV-3001) in combination with lifileucel for previously treated unresectable or metastatic…
NCT06940739 - New trial
Brain and CNS tumors
Phase I KIND T Cell Study Targets H3.3K27M Diffuse Midline Glioma
UCSF is launching a first-in-human trial evaluating autologous KIND T cells—engineered to express a TCR specific for the H3.3K27M mutation—following lymphodepletion with cyclophosphamide and fludarabine in…
NCT05478837 - New trial
Cervical and other gynecologic cancers
Phase II DURAFAK Trial Combines Dual RAF/MEK and FAK Inhibition in Recurrent Gynecological Cancers
The University of Oklahoma is evaluating the safety and efficacy of VS-6766 (avutometinib) together with defactinib in patients with recurrent endometrioid, mucinous ovarian, high-grade serous ovarian, or solid…
NCT05512208 - New trial
Sarcoma and GIST
Preoperative Hypofractionated Radiotherapy Trial Targets Soft Tissue Sarcoma
The Medical University of South Carolina is testing a 5-day preoperative hypofractionated radiotherapy regimen using Gamma Tile brachytherapy to treat soft tissue sarcoma while preserving surrounding healthy tissue.…
NCT05512208 - New trial
Kidney cancer
Risk-Adapted Treatment Trial for Unilateral Favorable Histology Wilms Tumors
The Children's Oncology Group is conducting a phase III trial that tailors treatment intensity for pediatric unilateral FHWT based on tumor histology, biology, and response to therapy. This comprehensive study…
NCT06401330 - New trial
Kidney cancer
Phase II Study of Ivonescimab in Advanced Clear Cell RCC
M.D. Anderson Cancer Center in Houston is evaluating ivonescimab—a PD-1 and VEGF bispecific antibody—administered IV every three weeks in patients with advanced clear cell RCC who have progressed on prior…
NCT06940518 - New trial
Other cancers
Indiana University Trials Maintenance Zanzalintinib with Oral Etoposide in Relapsed Metastatic GCT
This open-label phase I/II study evaluates the safety and optimal dosing of zanzalintinib, a c-Met/VEGFR inhibitor, in combination with oral etoposide following high-dose chemotherapy and PBSCT in patients with…
NCT06937866 - New trial
Ovarian cancer
Adaptive Trial Evaluates COM701 Maintenance in Relapsed Platinum-Sensitive Ovarian Cancer
Compugen Ltd is investigating COM701—a poliovirus receptor-related immunoglobulin-directed antibody—as a maintenance treatment to delay progression in patients with relapsed platinum sensitive ovarian cancer in a…
NCT06888921 - New trial
Uterine (endometrial) cancer
RESOLVE Trial Evaluates Multi-Agent Targeted Combinations in Recurrent ER+ Endometrial and Ovarian Cancer
Dana-Farber Cancer Institute is leading a multi-cohort phase II study assessing different targeted regimens—combining letrozole with abemaciclib alone or with LY3023414, metformin, or zotatifin—in patients with…
NCT03675893 - Trial result
Multiple solid tumors
Triple DDR Assault: ART0380 and Low-Dose Irinotecan Yield High Responses in ATM-Negative Tumors
In this first-in-human study, advanced cancer patients received ART0380 (ATR inhibitor) with low-dose irinotecan, with the recommended phase 2 dose established at 200mg ART0380 on days 1-3 and 8-10 and irinotecan at…
- Trial result
Multiple solid tumors
KVA12123, a Novel Anti-VISTA Antibody, Shows Promising Safety and Signs of Efficacy in Advanced Solid Tumors
In the first-in-human Phase 1 VISTA-101 trial, KVA12123—administered alone and with pembrolizumab—demonstrated a favorable safety profile (no dose-limiting toxicities or cytokine release syndrome) across doses up to…
- Trial result
Multiple solid tumors
FMT Enhances Immunotherapy Response While Influencing Toxicity Profiles in Lung Cancer and Melanoma
In the FMT-LUMINATE trial, patients with advanced NSCLC receiving ⍺PD-1 and melanoma patients treated with dual ICI underwent fecal microbiota transplantation (FMT) from healthy donors, resulting in high objective…
- Trial result
Multiple solid tumors
First-in-Human WRN Inhibitor RO7589831 Shows Promise in Hard-to-Treat MSI/dMMR Cancers
In this Phase 1 trial, RO7589831—a novel, covalent Werner helicase inhibitor—was administered orally at doses from 150 mg to 2000 mg in 44 patients with MSI/dMMR advanced solid tumors, including colorectal, ovarian,…
- Trial result
Multiple solid tumors
ANK-101 Anchored IL-12 Conjugate Elicits Local Immune Activation and Durable Disease Control in Advanced Solid Tumors
In this first-in-human Phase 1 study of ANK-101—an IL-12 conjugated to aluminum hydroxide—administered in a dose-escalation design in heavily pretreated patients with accessible advanced solid tumors, the treatment…
- Trial result
Multiple solid tumors
AMG 404, a New PD-1 Inhibitor, Advances in Early-Phase Trials for Advanced Solid Tumors
In this first-in-human Phase I study of AMG 404, administered every 4 weeks at escalating doses (240, 480, and 1050 mg) across 168 treated patients, the drug demonstrated no dose-limiting toxicities,…
- New trial
Multiple solid tumors
DLL3-Targeting Theranostic Agent Explored in High-grade Neuroendocrine Cancers
Memorial Sloan Kettering is evaluating the safety of 177Lu-DTPA-SC16.56 for relapsed, advanced small-cell lung and neuroendocrine prostate cancers. This study leverages PET/CT imaging to determine the theranostic…
NCT06941480 - New trial
Multiple solid tumors
Intraoperative PET-CT Enhances Margin Visualization in Solid Tumor Resections
Vanderbilt-Ingram Cancer Center is exploring the use of 18F-FDG and the XEOS Aura 10 PET/CT device for high-resolution, ex vivo imaging of resection margins during standard surgical procedures. This technique aims to…
NCT06915454 - New trial
Multiple solid tumors
Phase 1a/1b Trial of BBO-11818 in Advanced KRAS Mutant Cancers
BridgeBio Oncology is conducting a first-in-human study to assess the safety, pharmacokinetics, and preliminary antitumor activity of BBO-11818—a pan-KRAS inhibitor—in advanced, unresectable, or metastatic KRAS…
NCT06917079 - New trial
Multiple solid tumors
Phase 1/2 Trial Evaluates INBRX-106 with Pembrolizumab in Advanced Solid Tumors
Inhibrx Biosciences is launching an open-label, multi-part study to determine the safety, maximum tolerated dose, and potential antitumor activity of INBRX-106—an OX40-targeted agonist protein—administered alone or…
NCT04198766 - New trial
Multiple solid tumors
First-in-Human Study of DS-1471a in Advanced Solid Tumors
Daiichi Sankyo is conducting a phase 1 study to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of DS-1471a—a CD147-directed monoclonal antibody—in patients with advanced or metastatic…
NCT06074705
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.